Publicaciones RedinRen

• Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.

  Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T et al.. Am J Kidney Dis. 2014 Jul;64(1):74-85.

• Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression.

  Ruiz-Hurtado G, Condezo-Hoyos L, Pulido-Olmo H, Aranguez I, Del Carmen Gónzalez M, Arribas S et al.. J Hypertens. 2014 Oct;32(10):2082-91.

• Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to β2-Glycoprotein I.

  Morales JM, Martinez-Flores JA, Serrano M, Castro MJ, Alfaro FJ, García F et al.. J Am Soc Nephrol. 2014 Jul 28;.

• Mycophenolate in refractory and relapsing lupus nephritis

  Rivera, F, Mérida, E; Illescas, ML; López-Rubio, E; Frutos, MA; García-Frías, P; Ramos, C; Sierra, M; Baltar, J; Lucas, J; Oliet, A; Vigil, A; Fernández-Juárez, G; Segarra A; Praga, M.. Am J Nephrol. 2014;40(2):105-112.

• Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus

  Caro, J; Gutiérrez-Solís, E; Rojas-Rivera, J; Agraz, I; Ramos, N; Rabasco, C; Espinosa, M; Valera, A; Martín, M; Frutos, MA; Perea, L; Juárez, GF; Ocaña, J; Arroyo, D; Goicoechea, M; Fernández, L; Oliet, A; Hernández, Y; Romera, A; Segarra, A; Praga, M; for the Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN).. Nephrology Dialysis and Transplantation. 2014;.

• Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment.

  Polanco N, Gutiérrez E, Rivera F, Castellanos I, Baltar J, Lorenzo D. Nephrol Dial Transplant. 2012 Jan;27(1):231-4.

• The effect of weight loss in obesity and chronic kidney disease.

  Morales E, Praga M. Curr Hypertens Rep. 2012 Apr;14(2):170-6.

• Hepatitis C-induced renal disease in patients with AIDS: an emergent problem.

  Praga M, Gutiérrez Solís E, Morales E. Contrib Nephrol. 2012;176:24-34.

• IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality.

  Serrano A, García F, Serrano M, Ramírez E, Alfaro FJ, Lora D. Kidney Int. 2012 Jun;81(12):1239-44.

• Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.).

  Ruiz Irastorza G, Espinosa G, Frutos MA, Jiménez Alonso J, Praga M, Pallarés L. Nefrologia. 2012;32 Suppl 1:1-35.

• Lupus nephritis: in search of a better future.

  Frutos MÁ, Praga M, Quereda C, Rivera F, Segarra A. Nefrologia. 2012;32(2):136-8.

• Glomerular disease: Predicting outcomes in idiopathic membranous nephropathy.

  Praga M, Rojas-Rivera J. Nat Rev Nephrol. 2012 Sep;8(9):496-8.

• Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

  Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH. Ann Rheum Dis. 2012 Nov;71(11):1771-82.

• Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.

  Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M. Am J Kidney Dis. 2013 Feb;61(2):211-8.

• Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria.

  Gutiérrez E, Zamora I, Ballarín JA, Arce Y, Jiménez S, Quereda C. J Am Soc Nephrol. 2012 Oct;23(10):1753-60.

• Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.

  Morales E, Millet VG, Rojas-Rivera J, Huerta A, Gutiérrez E, Gutiérrez-Solís E. Nephrol Dial Transplant. 2013 Feb;28(2):405-12.

• Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors.

  Caro J, Morales E, Gutierrez E, Ruilope LM, Praga M. J Clin Hypertens (Greenwich). 2013 Mar;15(3):215-6.

• Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension.

  Cerezo C, Segura J, Praga M, Ruilope LM. Curr Hypertens Rep. 2013 Jun;15(3):196-203.

• Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients.

  Gonzalez E, Rojas-Rivera J, Polanco N, Morales E, Morales JM, Egido J. Transplantation. 2013 Apr 15;95(7):e49-52.

• Two cases of glomerulonephritis in one patient infected with the hepatitis C virus.

  Molina M, Sánchez J, Sevillano ÁM, Bengoa I, Gutiérrez E, Martínez MA. Nefrologia. 2013;33(4):593-600.

• 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.

  Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M. Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6.

• Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

  de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H. N Engl J Med. 2013 Dec 26;369(26):2492-503.

• Compliance with mineral metabolism targets in haemodialysis patients: moving backwards?

  Palomares I, Ramos R, Martin-Malo A, Merello JI, Praga M, Luño J. Blood Purif. 2013;36(2):122-31.

• [Persistent microhaematuria with negative or low proteinuria].

  Gutiérrez E, Moreno JA, Praga M, Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Nefrologia. 2014;34(1):110-4.

• Association of c4d deposition with clinical outcomes in IgA nephropathy.

  Espinosa M, Ortega R, Sánchez M, Segarra A, Salcedo MT, González F. Clin J Am Soc Nephrol. 2014 May;9(5):897-904.

• suPAR and focal segmental glomerulosclerosis.

  Praga M. Nefrologia. 2014;34(2):145-8.

• Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.

  Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J. Kidney Int. 2014 Apr 2;.

• Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease.

  de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM. Lancet Diabetes Endocrinol. 2014 May;2(5):417-426.

• Type of vascular access and survival among very elderly hemodialysis patients.

  Praga M, Merello JI, Palomares I, Bayh I, Marcelli D, Aljama P. Nephron Clin Pract. 2013;124(1-2):47-53.

• Oxidative stress, macrophage infiltration and CD163 expression are determinants of long-term renal outcome in macrohematuria-induced acute kidney injury of IgA nephropathy.

  Gutiérrez E, Egido J, Rubio-Navarro A, Buendía I, Blanco Colio LM, Toldos O. Nephron Clin Pract. 2012;121(1-2):c42-53.